Increasing local levels of neuregulin (glial growth factor-2) by direct infusion into areas of demyelination does not alter remyelination in the rat CNS - PubMed (original) (raw)

Comparative Study

Increasing local levels of neuregulin (glial growth factor-2) by direct infusion into areas of demyelination does not alter remyelination in the rat CNS

Jacques Penderis et al. Eur J Neurosci. 2003 Oct.

Abstract

Glial growth factor-2 (GGF-2) is a neuronally derived isoform of neuregulin shown in vitro to promote proliferation and survival of oligodendrocytes, the myelinating cells of the CNS. Enhanced remyelination has been demonstrated in vivo following systemic delivery of human recombinant GGF-2 (rhGGF-2) in experimental autoimmune encephalomyelitis (EAE). However, it is uncertain whether this is the result of direct effects of rhGGF-2 on cells of the oligodendrocyte lineage or due to modulation of the immune or inflammatory response. If this enhanced remyelination was due to direct effects of rhGGF-2 on cells of the oligodendrocyte lineage then one would expect rhGGF-2 to induce a similar proremyelinating response in nonimmune, gliotoxin models of demyelination. Using a gliotoxin model of demyelination we were therefore able to ascertain the in vivo effect of rhGGF-2 following local CNS delivery in a model that is not confounded by the concurrent presence of an immune-mediated process. No significant alteration in the rate or character of remyelination was evident following local delivery as compared to controls, and indeed nor following systemic delivery in the gliotoxin model. The results of this study therefore indicate that both direct infusion and systemic delivery of rhGGF-2 do not alter remyelination in a nonimmune, gliotoxin model of demyelination. This suggests that the proremyelinating effects of systemically delivered rhGGF-2 in EAE are unlikely to be due to direct effects on the oligodendrocyte lineage, but may be mediated by rhGGF-2 inducing an environment more favourable to remyelination, possibly through modulation of the immune response.

PubMed Disclaimer

Cited by

Newly Identified Deficiencies in the Multiple Sclerosis Central Nervous System and Their Impact on the Remyelination Failure.
Scalabrino G. Scalabrino G. Biomedicines. 2022 Mar 30;10(4):815. doi: 10.3390/biomedicines10040815. Biomedicines. 2022. PMID: 35453565 Free PMC article. Review.
Neuregulin-1 controls an endogenous repair mechanism after spinal cord injury.
Bartus K, Galino J, James ND, Hernandez-Miranda LR, Dawes JM, Fricker FR, Garratt AN, McMahon SB, Ramer MS, Birchmeier C, Bennett DL, Bradbury EJ. Bartus K, et al. Brain. 2016 May;139(Pt 5):1394-416. doi: 10.1093/brain/aww039. Epub 2016 Mar 17. Brain. 2016. PMID: 26993800 Free PMC article.
Neuronal activity regulates remyelination via glutamate signalling to oligodendrocyte progenitors.
Gautier HO, Evans KA, Volbracht K, James R, Sitnikov S, Lundgaard I, James F, Lao-Peregrin C, Reynolds R, Franklin RJ, Káradóttir RT. Gautier HO, et al. Nat Commun. 2015 Oct 6;6:8518. doi: 10.1038/ncomms9518. Nat Commun. 2015. PMID: 26439639 Free PMC article.
Glia Disease and Repair-Remyelination.
Franklin RJ, Goldman SA. Franklin RJ, et al. Cold Spring Harb Perspect Biol. 2015 May 18;7(7):a020594. doi: 10.1101/cshperspect.a020594. Cold Spring Harb Perspect Biol. 2015. PMID: 25986556 Free PMC article. Review.
Mechanisms of cell-cell interaction in oligodendrogenesis and remyelination after stroke.
Itoh K, Maki T, Lok J, Arai K. Itoh K, et al. Brain Res. 2015 Oct 14;1623:135-49. doi: 10.1016/j.brainres.2015.04.039. Epub 2015 May 8. Brain Res. 2015. PMID: 25960351 Free PMC article. Review.

Increasing local levels of neuregulin (glial growth factor-2) by direct infusion into areas of demyelination does not alter remyelination in the rat CNS - PubMed (original) (raw)